<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995033</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 08-5-066</org_study_id>
    <secondary_id>ZonMw 40-00812-98-07-004</secondary_id>
    <secondary_id>ZonMw 61200014</secondary_id>
    <secondary_id>Nabi-4508</secondary_id>
    <nct_id>NCT00995033</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of NicVAX速 Co-administered With Varenicline (Champix速)</brief_title>
  <official_title>A Phase 2B, Multi-Center, Randomized, Double-Blinded, Parallel-Arm , Study to Assess Efficacy and Safety of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX速) or Placebo Co-Administered With Varenicline (Champix速) as an Aid in Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nabi Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of NicVAX co-administered
      with varenicline as an aid in smoking cessation over a one-year period in smokers who want to
      quit smoking.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Long term abstinence</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, immunogenicity</measure>
    <time_frame>continuous assessment throughout the one year study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abstinence</measure>
    <time_frame>continuous assessment throughout the one year study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lapse and relapse rate</measure>
    <time_frame>continuous assessment throughout the one year study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawal symptoms</measure>
    <time_frame>continuous assessment throughout the one year study duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">558</enrollment>
  <condition>Smoking Behavior</condition>
  <condition>Smoking Lapse Behavior</condition>
  <condition>Smoking Relapse Behavior</condition>
  <arm_group>
    <arm_group_label>NicVAX conjugate vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Biological</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NicVAX vaccine</intervention_name>
    <description>NicVAX vaccine given 6 times over 6 months</description>
    <arm_group_label>NicVAX conjugate vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)</description>
    <arm_group_label>NicVAX conjugate vaccine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Champix</other_name>
    <other_name>Chantix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Smokes at least 10 cigarettes per day

          -  Good general health

          -  Negative pregnancy test prior to study entry

        Exclusion Criteria:

          -  Prior exposure to NicVAX or any other nicotine vaccine

          -  Known allergic reaction to alum or any of the components of the vaccine

          -  Use of systemic steroids, immunosuppressive agents or other medication that might
             interfere with an immune response

          -  Cancer or cancer treatment in the last 5 years

          -  HIV infection

          -  History of drug or alcohol abuse or dependence within 12 months

          -  Significant cardiovascular, hepatic, renal, psychiatric and/or respiratory disease

          -  Previous intolerance to varenicline

          -  Inability to fulfill all visits for approximately 54 weeks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Onno van Schayck, Professor Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6200 MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital/ Smoking Cessation Clinic</name>
      <address>
        <city>Amsterdam</city>
        <state>Noord-Holland</state>
        <zip>1006 BK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 6, 2009</study_first_submitted>
  <study_first_submitted_qc>October 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2009</study_first_posted>
  <last_update_submitted>February 18, 2013</last_update_submitted>
  <last_update_submitted_qc>February 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking cessation</keyword>
  <keyword>Smoking lapse behavior</keyword>
  <keyword>Smoking Relapse behavior</keyword>
  <keyword>Varenicline</keyword>
  <keyword>Nicotine conjugate vaccine</keyword>
  <keyword>Medication effect on smoking lapse behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

